Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
34 authors.
Ivana Kirilova KanchevaDepartment of Radiology, Leiden University Medical Center, the Netherlands.ORCID 0000-0002-1151-6243
Arabella BouziguesDementia Research Center, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID 0000-0002-0267-8590
Lucy Louise RussellDementia Research Center, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID 0000-0001-5023-5893
Phoebe H FosterDementia Research Center, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID 0000-0001-6300-6598
Eve Ferry-BolderDementia Research Center, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID 0009-0006-5083-0901
John C Van SwietenDepartment of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.
Lize Corrine JiskootDepartment of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-1120-1858
Harro SeelaarDepartment of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.ORCID 0000-0003-1989-7527
Raquel Sánchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Spain.ORCID 0000-0001-7750-896X
Robert LaforceClinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Canada.ORCID 0000-0002-2031-490X
Caroline GraffDepartment of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Bioclinicum, Karolinska Institutet, Solna, Sweden.ORCID 0000-0002-9949-2951
Daniela GalimbertiFondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy.ORCID 0000-0002-9284-5953
Rik VandenbergheLaboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Belgium.ORCID 0000-0001-6237-2502
Pietro TiraboschiFondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.ORCID 0000-0002-2171-1720
Isabel SantanaUniversity Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Portugal.ORCID 0000-0002-8114-9434
Alexander GerhardDivision of Psychology Communication and Human Neuroscience, Wolfson Molecular Imaging Center, University of Manchester, United Kingdom.ORCID 0000-0002-8071-6062
Johannes LevinDepartment of Neurology, Ludwig-Maximilians Universität München, Germany.ORCID 0000-0001-5092-4306
Simon DucharmeDepartment of Psychiatry, McGill University Health Center, McGill University, Montreal, Québec, Canada.ORCID 0000-0002-7309-1113
Christopher ButlerNuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, United Kingdom.ORCID 0000-0002-7502-9284
Isabelle Le BerSorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, France.ORCID 0000-0002-2508-5181
Elizabeth FingerDepartment of Clinical Neurological Sciences, University of Western Ontario, London, Canada.ORCID 0000-0003-4461-7427
Maria Carmela TartagliaTanz Center for Research in Neurodegenerative Diseases, University of Toronto, Ontario, Canada.ORCID 0000-0002-5944-8497
Mario MasellisSunnybrook Health Sciences Center, Sunnybrook Research Institute, University of Toronto, Ontario, Canada.ORCID 0000-0002-6244-2096
Matthis SynofzikDepartment of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Germany.ORCID 0000-0002-2280-7273
Fermin MorenoCognitive Disorders Unit, Department of Neurology, Donostia Universitary Hospital, San Sebastian, Spain.ORCID 0000-0001-5200-3164
Barbara BorroniDepartment of Clinical and Experimental Sciences, University of Brescia, Italy.ORCID 0000-0001-9340-9814
Jonathan Daniel RohrerDementia Research Center, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID 0000-0002-6155-8417
Louise van der WeerdDepartment of Radiology, Leiden University Medical Center, the Netherlands.
James B RoweDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom.ORCID 0000-0001-7216-8679
Kamen TsvetanovDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom.ORCID 0000-0002-3178-6363
GENFI Consortium
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
BACKGROUND AND
objectivesCerebrovascular reactivity (CVR) is an indicator of cerebrovascular health, and its signature in familial frontotemporal dementia (FTD) remains unknown. The primary aim was to investigate CVR in genetic FTD using an fMRI index of vascular contractility termed resting-state fluctuation amplitudes (RSFAs) and to assess whether RSFA differences are moderated by age. A secondary aim was to study the relationship between RSFA and cognition.
methodsParticipants included presymptomatic and symptomatic
resultsA total of 284 presymptomatic and 124 symptomatic sequence variation carriers, and 265 noncarriers, were included in the analysis (mean age 48.17 years, 55% female). Across the sample, symptomatic carriers exhibited lower RSFA and a greater age-related RSFA decline predominantly in the medial frontal (-0.07 standard units, DISCUSSION: CVR impairment in genetic FTD has a predilection for the middle frontal and posterior cortex, and its preservation may yield a cognitive benefit for at-risk individuals. Although findings do not provide causality and warrant replication, they support the notion that vascular dysfunction in familial FTD may be a target for biomarker identification and disease-modifying efforts.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cerebrovascular Reactivity at Rest and Its Association With Cognitive Function in People With Genetic Frontotemporal Dementia. · full record | OpenQuestion